Intestinal Neoplasms Clinical Trial
Official title:
A Prospective Comparison of Diagnostic Efficacy and Radiomics Study in the Diagnosis and Therapeutic Efficacy Evaluation of Small Bowel Tumor With Dual-phase Enhanced Computed Tomography (CTE) and Magnetic Resonance Enterography (MRE)
Purpose: To compare the accuracies of computed tomographic (CT) enterography and magnetic resonance (MR) enterography for the detection and radiomics characterization of small-bowel tumors (including gastrointestinal stromal tumors, adenomas and lymphomas, etc); Hypothesis: MR enterography was noninferior to CT enterography for the diagnosis and evaluation of small bowel tumors in generally well-distended small bowel.
The investigators will conduct a 36-month clinical trial, the specific process is as follows:
1. Incorporate patients with the above criteria, communicate with the participants to make
informed consent and sign informed consent;
2. It is recommended that the attending physician issue the corresponding MRE checklist and
the CTE checklist and make an appointment to check the same day to remind the patient to
perform the corresponding bowel preparation work in advance, and perform renal function
tests within 3 days before the examination;
3. The enrolled patients were measured for height and weight, and the BMI was calculated.
CTE and MRE were performed according to the results of balanced randomization. The MRE
was performed on a 3.0T MRI scanner; the CTE examination was performed on a 320-row CT
scanner, and the iodine-containing contrast agent was administered according to the
patient's height and weight and GFR;
4. Both examinations require an empty stomach preparation (more than 4 hours), and oral
(1500ml) 2.5% mannitol aqueous solution before the examination to ensure intestinal
filling, subcutaneous indwelling needle preparation, in order to save patient
examination time, so the two examinations are completed within 6 hours, before the
second inspection, you need to add 150-300ml of 2.5% mannitol aqueous solution;
5. The images obtained were evaluated by two imaging physicians for lesions, numbers, size
changes, density/signal values, and peripheral tissue lesions obtained by the two
methods;
6. After the patient has obtained a definitive diagnosis according to the routine medical
procedure, the above imaging diagnosis results are compared with the confirmed diagnosis
results.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Recruiting |
NCT05322486 -
Palliative Primary Tumor Resection in Minimally Symptomatic Patients With Colorectal Cancer and Synchronous Unresectable Metastases
|
||
Completed |
NCT03559543 -
Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma
|
Phase 2 | |
Active, not recruiting |
NCT01037049 -
Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks
|
Phase 2 | |
Enrolling by invitation |
NCT06048146 -
A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis
|
N/A | |
Completed |
NCT04080843 -
Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC Patients
|
Phase 2 | |
Recruiting |
NCT03303495 -
A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
|
Phase 3 | |
Terminated |
NCT04644315 -
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
|
Phase 2 | |
Recruiting |
NCT03271255 -
Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)
|
Phase 2 | |
Completed |
NCT02785783 -
Endoringsā¢ Assisted Colonoscopy Versus Standard Colonoscopy for Polyp Detection
|
N/A | |
Recruiting |
NCT04949282 -
Spanish Series of Patients Treated With the Radionuclide Lutetium177
|
||
Completed |
NCT03037385 -
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03280407 -
NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01995942 -
Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial
|
||
Active, not recruiting |
NCT02202928 -
Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05193292 -
Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT04755920 -
SGM-101 in Colorectal Brain Metastases.
|
Phase 2 | |
Completed |
NCT03072472 -
BowelScope: Accuracy of Detection Using ENdocuff Optimisation of Mucosal Abnormalities
|
N/A | |
Completed |
NCT01996306 -
A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC
|
Phase 3 | |
Active, not recruiting |
NCT02005965 -
Low Rectal Cancer Study (MERCURY II)
|